Novavax Stock News

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company's earnings report for the fourth quarter of 2024. Let's dig into everything that has investors in NVA

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago.

Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.

Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.

Novavax fell behind in the coronavirus vaccine race, which has weighed heavily on its earnings potential and share price. The company is working to recover and spur growth down the road.

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th

Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi'

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

Novavax (NASDAQ: NVAX ) stock is taking off on Thursday after the company reached a settlement with global vaccine organization Gavi. This settlement has Novavax agreeing to pay up to $475 million to

The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

Novavax is making progress along the path to recovery -- and its combined COVID/flu vaccine candidate could drive growth. Pfizer offers better growth prospects than you might think, as well as a juicy

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had creat

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biote

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fou

After commercializing its first vaccine, Novavax is sputtering as it looks for a follow-up. Its pipeline is looking very thin, and it's being forced to scale down its operations.